Tarsus Pharmaceuticals Announces Agreement To Acquire Alkeus For $450M Upfront In Cash And Stock, Up To $350M In Milestones, Adding Phase 3 Stargardt Disease Therapy
Share
Why It Matters
Tarsus is buying another company's medicine that could treat an eye disease, paying $450 million now plus more money later if things go well. This shows Tarsus believes in this new treatment and is betting it will help patients and make money.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.